Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Phase III study of rituxan in lupus nephritis did not meet primary endpoint
[online]
(2009).
2. Isenberg, D., Gordon, C., Merrill, J. & Urowitz, M. New therapies in systemic lupus erythematosus—trials, troubles and tribulations... Working towards a solution. Lupus 17, 967–970 (2008).
3. Wallace, D. New therapies in systemic lupus erythematosus—trials, troubles and tribulations—working towards a solution: part 2—the politically incorrect version. Lupus 18, 101–103 (2009).
4. Waldman, M. & Appel, G. B. Update on the treatment of lupus nephritis. Kidney Int. 70, 1403–1412 (2006).
5. Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER [abstract L12]. Presented at the American College of Rheumatology Annual Meeting, 2008 October 24–29, San Francisco, CA.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献